Antibiotics in the Critically Ill Patient

Dear Colleagues,

Infectious issues have always been a major concern in the management of critically ill patients. Clinical features and the derangement of several physiological and pharmacological traits require a distinctive and careful approach.

As a result, intensivist physicians developed a high level of interest in the area of infections and an aptitude for multidisciplinary dialogue with microbiologists, infectious disease specialists, pharmacologists, and all professionals involved in these topics.

The introduction in clinical practice of molecular biology techniques and the release of a dozen new antibiotic molecules are leading to rapid generational change in the diagnostic/therapeutic paradigm.

The implementation of new tests and drugs into clinical practice requires high levels of understanding.

Furthermore, intensive care units have been overloaded over the past 3 years by the SARS-CoV-2 pandemic. COVID-19 patients, in addition to logistical problems, suffer from a high prevalence of bacterial over-infections, which are extremely difficult to diagnose and treat. The SARS-CoV-2 pandemic, therefore, led to the suspension of antimicrobial stewardship programs and the spread of multidrug-resistant germs in intensive care units.

Hence, we believe that a Special Issue of Antibiotics focusing on critically ill patients is of great significance. The aim is to report research, experiences, works, ideas, and strategies on these topics. We are looking for papers about innovative diagnostic techniques, recently introduced molecules, pharmacodynamic/pharmacokinetic features, epidemiological data, risk stratification strategy, and multidrug-resistant bacteria management.

Dr. Emanuele Russo
Dr. Vanni Agnoletti
Dr. Fausto Catena
Dr. Bruno Viaggi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.